search
Back to results

Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas

Primary Purpose

Perianal Fistula, Adipose Tissue, Tissue Transplantation

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Injection of autologous adipose tissue in anal fistula
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Perianal Fistula focused on measuring autologous adipose tissue, mesenchymal stem cells, perianal fistula

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • high trans-sphincteric fistulas
  • fistula confirmed and classified by an MRI.
  • seton (> 6 weeks) prior to fat injection
  • informed, written consent.

Exclusion Criteria:

Anovaginal fistula

  • Active sepsis
  • IBD, immunodeficiency, prior pelvic irradiation and malignancy
  • Insulin dependent diabetes
  • More than 4 prior attempts of fistula closure
  • Tobacco smoking or nicotine substitution 8 weeks prior to fat injection.
  • Pregnancy
  • Psychiatric disorders
  • BMI ≥ 35 or BMI<20
  • Active tuberculosis
  • Patient less than 18 years
  • Unable to undergo MRI

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Injection with adipose tissue

    Arm Description

    Injection of freshly collected autologous adipose tissue

    Outcomes

    Primary Outcome Measures

    Investigation of cell proliferation of AT-MSCs
    Cell proliferation of AT-MSCs evaluated as number of cells/per day
    Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte
    Differentiation potential of AT-MSCs: to differentiate into adipocyte measured by Oil-Red O staining and gene expression of adipogenic markers (PPARg and LPL normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
    Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast
    Differentiation potential of AT-MSCs: to differentiate into osteoblast measured by Alizarin S staining and gene expression of osteogenic markers (BGALP and RUNX2 normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
    Measurement of gene expression profile of AT-MSCs
    Gene expression of proinflammatory (NFKB, TNFa, IL1B, IL6) and senescence associated molecules(CDKN2A, TP53, TGFB1, VEGFA, IFNG, IL6) of AT-MSCs in relation to the outcome of fistula treatment (i.e. comparison between responders and non-responders). The data are normalized to housekeeping gene beta actin (arbitrary units)

    Secondary Outcome Measures

    Healing of anal fistula after treatment
    Clinical healing defined as closure of the internal and external fistula opening and no discharge evaluated as success rate of the healing in (%)
    Evaluation of fistula healing after treatment
    A combination of Clinical and MRI healing defined as closure of the internal and external fistula opening and no discharge and no fluid filled fistula tracts on evaluated as success rate of the healing in (%)
    Functional gastroenterological outcome after treatment
    Anal continence evaluated as the St. Mark's Score (0-24)
    Defecation disorder evaluation after treatment
    Defecation disorders evaluated as Altomare Obstructed Defecation Score (0-31)
    Functional urological outcome after treatment
    Urinary incontinence evaluated as ICIQ-UI-SF (0-21)

    Full Information

    First Posted
    March 22, 2021
    Last Updated
    April 6, 2021
    Sponsor
    University of Aarhus
    Collaborators
    University of Southern Denmark, UiT The Arctic University of Norway
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04834609
    Brief Title
    Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
    Official Title
    Identification of Molecular Differences of Adipose-derived Mesenchymal Stem Cells Between Non- Responders and Responders in Treatment of Transsphincteric Perianal Fistulas Using Autologous Fat Graft Injection
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2015 (Actual)
    Primary Completion Date
    October 2017 (Actual)
    Study Completion Date
    February 2021 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Aarhus
    Collaborators
    University of Southern Denmark, UiT The Arctic University of Norway

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study investigated the cellular and molecular characteristics of AT-MSCs obtained from autologous AT therapy in patients with high transphincteric perianal fistulas of crytoglandular origin. Adipose tissue was injected into anal fistulas. Characteristics of adipose tissue mesenchymal stemcells (AT-MSC) was investigated and compared in patients with fistula that healed after the treatment (responders) to patients who failed to heal (non-responders)
    Detailed Description
    Injection with allogene or autologous stem cells has been reported to be efficient treatment of perianal fistulas. An alternative to this treatment could be injection with freshly collected autologous adipose tissue. In this study 27 patients with cryptoglandular anal fistulas were treated with freshly collected autologous adipose tissue.A clinical assessment of the patient prior to inclusion was undertaken and a loose seton placed for at least 6 weeks prior to fat injection. An MRI of the pelvis was performed before inclusion. Fistulas with secondary tracts and/or cavities were excluded. The operation was performed in one procedure including liposuction and injection of adipose tissue. A sample of adipose tissue from all 27 patients was analyzed. AT-MSCs were isolated and characterized using cellular and molecular analyses. Clinical and MRI-scanning evaluation of fistula healing and evaluation of ano-rectal function was performed after 6 months. AT-MSCs phenotype was compared between responders and non-responders with respect to fistula healing. The evaluation of the AT-MSCs was performed in a blinded manner.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Perianal Fistula, Adipose Tissue, Tissue Transplantation
    Keywords
    autologous adipose tissue, mesenchymal stem cells, perianal fistula

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Masking Description
    Characterisation of adipose tissue (AT-MSCs) was performed blinded to the result of the treatment responder/non-responder
    Allocation
    N/A
    Enrollment
    27 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Injection with adipose tissue
    Arm Type
    Experimental
    Arm Description
    Injection of freshly collected autologous adipose tissue
    Intervention Type
    Procedure
    Intervention Name(s)
    Injection of autologous adipose tissue in anal fistula
    Primary Outcome Measure Information:
    Title
    Investigation of cell proliferation of AT-MSCs
    Description
    Cell proliferation of AT-MSCs evaluated as number of cells/per day
    Time Frame
    At start of treatment
    Title
    Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte
    Description
    Differentiation potential of AT-MSCs: to differentiate into adipocyte measured by Oil-Red O staining and gene expression of adipogenic markers (PPARg and LPL normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
    Time Frame
    At start of treatment
    Title
    Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast
    Description
    Differentiation potential of AT-MSCs: to differentiate into osteoblast measured by Alizarin S staining and gene expression of osteogenic markers (BGALP and RUNX2 normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units)
    Time Frame
    At start of treatment
    Title
    Measurement of gene expression profile of AT-MSCs
    Description
    Gene expression of proinflammatory (NFKB, TNFa, IL1B, IL6) and senescence associated molecules(CDKN2A, TP53, TGFB1, VEGFA, IFNG, IL6) of AT-MSCs in relation to the outcome of fistula treatment (i.e. comparison between responders and non-responders). The data are normalized to housekeeping gene beta actin (arbitrary units)
    Time Frame
    At start of treatment
    Secondary Outcome Measure Information:
    Title
    Healing of anal fistula after treatment
    Description
    Clinical healing defined as closure of the internal and external fistula opening and no discharge evaluated as success rate of the healing in (%)
    Time Frame
    6 months after last injection of autologous adipose tissue
    Title
    Evaluation of fistula healing after treatment
    Description
    A combination of Clinical and MRI healing defined as closure of the internal and external fistula opening and no discharge and no fluid filled fistula tracts on evaluated as success rate of the healing in (%)
    Time Frame
    6 months after last injection of autologous adipose tissue
    Title
    Functional gastroenterological outcome after treatment
    Description
    Anal continence evaluated as the St. Mark's Score (0-24)
    Time Frame
    6 months after last injection of autologous adipose tissue
    Title
    Defecation disorder evaluation after treatment
    Description
    Defecation disorders evaluated as Altomare Obstructed Defecation Score (0-31)
    Time Frame
    6 months after last injection of autologous adipose tissue
    Title
    Functional urological outcome after treatment
    Description
    Urinary incontinence evaluated as ICIQ-UI-SF (0-21)
    Time Frame
    6 months after last injection of autologous adipose tissue

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: high trans-sphincteric fistulas fistula confirmed and classified by an MRI. seton (> 6 weeks) prior to fat injection informed, written consent. Exclusion Criteria: Anovaginal fistula Active sepsis IBD, immunodeficiency, prior pelvic irradiation and malignancy Insulin dependent diabetes More than 4 prior attempts of fistula closure Tobacco smoking or nicotine substitution 8 weeks prior to fat injection. Pregnancy Psychiatric disorders BMI ≥ 35 or BMI<20 Active tuberculosis Patient less than 18 years Unable to undergo MRI

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    34819138
    Citation
    Tencerova M, Lundby L, Buntzen S, Norderval S, Hougaard HT, Pedersen BG, Kassem M. Molecular differences of adipose-derived mesenchymal stem cells between non-responders and responders in treatment of transphincteric perianal fistulas. Stem Cell Res Ther. 2021 Nov 24;12(1):586. doi: 10.1186/s13287-021-02644-8.
    Results Reference
    derived

    Learn more about this trial

    Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas

    We'll reach out to this number within 24 hrs